Corrigendum to “The modulatory effect of sodium molybdate against cisplatin-induced CKD: Role of TGF-β/Smad signaling pathway” Life Sci. Volume 306 1 October 2022, 120845
This corrigendum addresses the findings related to the effect of sodium molybdate on cisplatin-induced chronic kidney disease via TGF-β/Smad signaling.
Revised analyses related to the signaling mechanisms involved.
Clarified intervention effects observed in the chronic kidney disease model.
Sodium molybdate significantly decreased levels of TGF-β in the affected kidney tissues.
Improved renal function markers were associated with modulation of the Smad signaling pathway.